Janus Henderson Group PLC Argenx Se Transaction History

Janus Henderson Group PLC

$182 Billion
Q2 2024

A detailed history of Janus Henderson Group PLC transactions in Argenx Se stock. As of the latest transaction made, Janus Henderson Group PLC holds 2,468,232 shares of ARGX stock, worth $1.47 Billion. This represents 0.58% of its overall portfolio holdings.

Number of Shares

2,468,232

Previous 2,216,648 11.35%

Holding current value

$1.47 Billion

Previous $873 Million 21.62%

% of portfolio

0.58%

Previous 0.49%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$356.01 - $451.55 $89.6 Million - $114 Million	251,584 Added 11.35%	2,468,232 $1.06 Billion
Q1 2024 May 15, 2024	BUY	$356.95 - $413.29 $157 Million - $182 Million	439,889 Added 24.76%	2,216,648 $873 Million
Q4 2023 Feb 14, 2024	BUY	$338.91 - $506.01 $104 Million - $155 Million	305,621 Added 20.77%	1,776,759 $676 Million
Q3 2023 Nov 14, 2023	SELL	$369.35 - $548.43 $115 Million - $171 Million	-312,315 Reduced 17.51%	1,471,138 $723 Million
Q2 2023 Aug 14, 2023	SELL	$360.14 - $422.58 $4.09 Million - $4.8 Million	-11,357 Reduced 0.63%	1,783,453 $695 Million
Q1 2023 May 15, 2023	BUY	$334.23 - $403.65 $274 Million - $331 Million	820,090 Added 84.14%	1,794,810 $669 Million
Q4 2022 Feb 14, 2023	BUY	$342.17 - $402.31 $141 Million - $166 Million	412,435 Added 73.35%	974,720 $369 Million
Q3 2022 Nov 14, 2022	SELL	$343.2 - $395.75 $1.35 Million - $1.56 Million	-3,931 Reduced 0.69%	562,285 $199 Million
Q2 2022 Aug 15, 2022	SELL	$269.58 - $378.88 $11.6 Million - $16.3 Million	-42,935 Reduced 7.05%	566,216 $215 Million
Q1 2022 May 16, 2022	BUY	$254.45 - $351.06 $4.7 Million - $6.49 Million	18,490 Added 3.13%	609,151 $192 Million
Q4 2021 Feb 14, 2022	BUY	$272.01 - $353.03 $18.4 Million - $23.9 Million	67,723 Added 12.95%	590,661 $207 Million
Q3 2021 Nov 16, 2021	BUY	$295.0 - $350.58 $7.34 Million - $8.72 Million	24,878 Added 4.99%	522,938 $158 Million
Q2 2021 Aug 16, 2021	BUY	$257.11 - $319.92 $11.3 Million - $14 Million	43,772 Added 9.64%	498,060 $150 Million
Q1 2021 May 17, 2021	BUY	$268.3 - $380.31 $40.7 Million - $57.7 Million	151,667 Added 50.12%	454,288 $125 Million
Q4 2020 Feb 16, 2021	BUY	$248.13 - $308.36 $14.8 Million - $18.4 Million	59,657 Added 24.55%	302,621 $89 Million
Q3 2020 Nov 16, 2020	SELL	$215.51 - $272.51 $11.6 Million - $14.6 Million	-53,683 Reduced 18.1%	242,964 $63.8 Million
Q2 2020 Aug 14, 2020	SELL	$127.44 - $232.72 $285,720 - $521,758	-2,242 Reduced 0.75%	296,647 $66.8 Million
Q1 2020 May 14, 2020	SELL	$108.83 - $165.23 $3.78 Million - $5.73 Million	-34,708 Reduced 10.4%	298,889 $39.4 Million
Q4 2019 Feb 18, 2020	BUY	$106.59 - $164.21 $3.79 Million - $5.83 Million	35,533 Added 11.92%	333,597 $53.5 Million
Q3 2019 Nov 14, 2019	SELL	$113.31 - $150.51 $1.56 Million - $2.07 Million	-13,730 Reduced 4.4%	298,064 $34 Million
Q2 2019 Jul 31, 2019	SELL	$115.0 - $141.58 $5.88 Million - $7.24 Million	-51,124 Reduced 14.09%	311,794 $44.1 Million
Q1 2019 Apr 30, 2019	SELL	$98.85 - $134.59 $7.72 Million - $10.5 Million	-78,146 Reduced 17.72%	362,918 $45.3 Million
Q4 2018 Feb 06, 2019	SELL	$63.81 - $109.82 $3.36 Million - $5.77 Million	-52,585 Reduced 10.65%	441,064 $42.4 Million
Q3 2018 Nov 09, 2018	BUY	$75.5 - $96.63 $4.01 Million - $5.13 Million	53,070 Added 12.05%	493,649 $37.4 Million
Q2 2018 Aug 10, 2018	BUY	$74.84 - $100.16 $333,561 - $446,413	4,457 Added 1.02%	440,579 $36.5 Million
Q1 2018 May 14, 2018	SELL	$56.95 - $85.19 $7.36 Million - $11 Million	-129,163 Reduced 22.85%	436,122 $35.1 Million
Q4 2017 Feb 09, 2018	BUY	$22.57 - $63.56 $12.8 Million - $35.9 Million	565,285	565,285 $35.7 Million

Others Institutions Holding ARGX

# of Institutions

393

Shares Held

31.8M

Call Options Held

361K

Put Options Held

449K

View Full List

About ARGENX SE

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $32.9B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

More about ARGX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Janus Henderson Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Janus Henderson Group PLC with notifications on news.

Account

Janus Henderson Group PLC Argenx Se Transaction History